Dow Down3.39% Nasdaq Down4.12%

More On ANP.AX



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Antisense Therapeutics Ltd. (ANP.AX)

0.03 Down 0.00(6.06%) Jun 24, 12:49AM EDT
ProfileGet Profile for:
Antisense Therapeutics Ltd.
6 - 8 Wallace Avenue
Toorak, VIC 3142
Australia - Map
Phone: 61 3 9827 8999
Fax: 61 3 9827 1166

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:8

Business Summary 

Antisense Therapeutics Ltd. engages in the research, development, and commercialization of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. The company has a partnership with Isis Pharmaceuticals, Inc. for the discovery and development of antisense drugs. Antisense Therapeutics Ltd. is based in Toorak, Australia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Antisense Therapeutics Ltd.

Key Executives 
Mr. Mark Diamond BSc, MBA, MAICD,
Chief Exec. Officer, Managing Director and Director
Mr. Phillip Allen Hains BBus(Acc), MBA, CA, 57
Chief Financial Officer and Company Sec.
Dr. George Tachas ,
Director of Drug Discovery & Patents
Susan Turner ,
Exec. Officer
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in AUD.